Literature DB >> 2118493

Prognostic factors in the radiotherapy of Graves' ophthalmopathy.

I A Petersen1, J P Kriss, I R McDougall, S S Donaldson.   

Abstract

Between April 1968 and February 1988, 311 patients with symptomatic and progressive Graves' ophthalmopathy were treated with megavoltage orbital radiotherapy. The patients were divided into three groups: I (156 patients) treated with 20 Gy/2 weeks; II (69 patients) treated with 30 Gy/3 weeks, and III (a most recent set of 86 patients) received 20 Gy/2 weeks. The degree of eye involvement was evaluated numerically before and after therapy for each of five parameters: soft tissue signs, proptosis, eye muscle impairment, corneal involvement, and sight loss. Pre-treatment and current thyroid diagnosis and status were also noted. To evaluate the effects of radiotherapy alone, follow-up was terminated at the time any eye surgery was done; for those not treated surgically the minimum follow-up was 12 months. Because there were significant demographic differences between the patient groups, the results of each group were analyzed separately. A stepwise linear regression analysis was performed to determine if there were any significant variables affecting outcome. Based on these data formulae were derived which enable outcome to be predicted in any patient. Before therapy more than 90% of patients in all groups had soft tissue and eye muscle involvement, whereas 65-75% had proptosis and about half 50% had some degree of sight loss. Radiotherapy arrested progression of ophthalmic parameters in all but 1-6% of the patients. Objective and symptomatic improvement was noted for all parameters assessed, but there was marked individual variability. The best responses were noted for soft tissue, corneal involvement, and sight loss; however over half the patients had some improvement in eye muscle function and proptosis. Factors which resulted in less favorable outcome included male gender, advanced age, need for concurrent therapy for hyperthyroidism, and no history of hyperthyroidism. No complications have been observed. No significant differences in outcome were observed between the two dosage schedules. Following radiotherapy 29% of patients subsequently underwent some form of eye surgery, mostly eye muscle surgery to correct diplopia. After radiotherapy corticosteroid therapy was stopped without relapse in 76%. Orbital radiotherapy can result in improvement in signs and symptoms of Graves' ophthalmopathy in the majority of patients. For the remainder of patients the disease manifestations can be stabilized to allow functional surgical correction.

Entities:  

Mesh:

Year:  1990        PMID: 2118493     DOI: 10.1016/0360-3016(90)90532-o

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

Review 1.  Does radiotherapy have a role in the management of thyroid orbitopathy? View 1.

Authors:  Kimberley P Cockerham; John S Kennerdell
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

Review 2.  Management of dysthyroid eye disease.

Authors:  P Fells
Journal:  Br J Ophthalmol       Date:  1991-04       Impact factor: 4.638

3.  Effect of radiotherapy on moderate and severe thyroid associated ophthalmopathy: a double blind and self-controlled study.

Authors:  Yujie Wu; Boding Tong; Yongheng Luo; Guiyuan Xie; Wei Xiong
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 4.  Thyroid eye disease.

Authors:  D H Char
Journal:  Br J Ophthalmol       Date:  1996-10       Impact factor: 4.638

5.  DEGRO practical guidelines for the radiotherapy of non-malignant disorders - Part IV: Symptomatic functional disorders.

Authors:  Gabriele Reinartz; Hans Theodor Eich; Fabian Pohl
Journal:  Strahlenther Onkol       Date:  2014-12-09       Impact factor: 3.621

6.  Feasibility of tomotherapy for Graves' ophthalmopathy: Dosimetry comparison with conventional radiotherapy.

Authors:  Nam P Nguyen; Shane P Krafft; Paul Vos; Vincent Vinh-Hung; Misty Ceizyk; Siyoung Jang; Anand Desai; Dave Abraham; Lars Ewell; Christopher Watchman; Russ Hamilton; Beng-Hoey Jo; Ulf Karlsson; Lexie Smith-Raymond
Journal:  Strahlenther Onkol       Date:  2011-06-28       Impact factor: 3.621

7.  Orbital radiotherapy for Graves' ophthalmopathy: useful or useless? Safe or dangerous?

Authors:  L Bartalena; C Marcocci; C A Gorman; W M Wiersinga; A Pinchera
Journal:  J Endocrinol Invest       Date:  2003-01       Impact factor: 4.256

8.  A case of radiation retinopathy of left eye after radiation therapy of right brain metastasis.

Authors:  Kwon Ho Hong; Sung Dong Chang
Journal:  Korean J Ophthalmol       Date:  2009-06-09

9.  Risk factors associated with the severity of thyroid-associated orbitopathy in Korean patients.

Authors:  Ji Hwan Lee; Sang Yeul Lee; Jin Sook Yoon
Journal:  Korean J Ophthalmol       Date:  2010-10-05

10.  The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota.

Authors:  G B Bartley
Journal:  Trans Am Ophthalmol Soc       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.